Radioimmunotherapy
Top View
- Trends in Radiopharmaceuticals
- Y-90 Ct84.66), GEMCITABINE and HEPATIC ARTERIAL INFUSION of FUDR for METASTATIC COLORECTAL CARCINOMA to the LIVER
- Y90 Ibritumomab Tiuxetan and I131 Tositumomab
- Practical and Clinical Benefits of Radioimmunotherapy Lead To
- Acr–Acnm–Astro–Snmmi Practice Parameter for the Performance of Therapy with Unsealed Radiopharmaceutical Sources
- Radioimmunotherapy for Metastatic Prostate Cancer
- Radionuclide Metabolic Therapy Clinical Aspects, Dosimetry and Imaging
- 90Y)-Ibritumomab Tiuxetan Radioimmunotherapy (Zevalin®
- What's in a Label? Radioimmunotherapy for Metastatic Prostate Cancer
- Clinical Appropriateness Guidelines
- Radiosurgery Or Hypofractionated Stereotactic Radiotherapy for Brain Metastases from Radioresistant Primaries (Melanoma and Rena
- RIT): Moving Forward Jordan M
- A Primer for Radioimmunotherapy and Radionuclide Therapy
- The Treatment of Low-Grade B-Cell Non-Hodgkin's Lymphomas With
- Radioimmunotherapy of Small Cell Lung Carcinoma with The
- Therapeutic Efficacy of C-Kit-Targeted Radioimmunotherapy Using 90Y-Labeled Anti-C-Kit Antibodies in a Mouse Model of Small Cell Lung Cancer
- 131-Labeled Anti-CEA Monoclonal Antibody NP-4 F(Ab')2
- Yttrium-90-Labeled Anti-CD2O Monoclonal Antibody Therapy of Recurrent B-Cell Lymphoma’